Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients
Matthew R. Wilson(Beatson West of Scotland Cancer Centre), Fiona Miall(University Hospitals of Leicester NHS Trust), Nathalie Forgeard(Sorbonne Université), Nimish Shah(National Health Service), Brett Barlow(University of Alabama at Birmingham), Mayur Narkhede(University of Alabama at Birmingham), Kate Manos(Austin Hospital), Charlotte Lees(Churchill Hospital), Francesco Vassallo(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Sylvain Choquet(Sorbonne Université), Kossi Agbétiafa(Hôpital René Huguenin), Amy A. Kirkwood(Cancer Research UK), Timothy Ebsworth(University Hospital Southampton NHS Foundation Trust), Adam Zayac(Rutgers, The State University of New Jersey), Anna Santarsieri(Cambridge University Hospitals NHS Foundation Trust), Thura Win Htut(Aberdeen Royal Infirmary), Katharine L. Lewis(Linear Clinical Research), Matthew J. Ahearne(University of Leicester), Carole Soussain(Institut Curie), Tim Strüßmann(University Medical Center Freiburg), Graham McIlroy(NIHR Surgical Reconstruction and Microbiology Research Centre), Nicolás Martínez‐Calle(Nottingham University Hospitals NHS Trust), Éric Durot(Centre Hospitalier Universitaire de Reims), Naëlle Lombion(Hôpital André Mignot), Emmanuelle Tchernonog(Centre Hospitalier Universitaire de Montpellier), Elisabeth Schorb(University Medical Center Freiburg), Laure Lebras(Centre Léon Bérard), Jeffery Smith(University of Liverpool), Toby A. Eyre(Oxford University Hospitals NHS Trust), Jahanzaib Khwaja(University College Hospital), Anna Guidetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Hamish W Scott(St Vincent’s Private Hospital Sydney), Andreas Kiesbye Øvlisen(Aalborg University Hospital), Loïc Renaud(Assistance Publique – Hôpitaux de Paris), Alberto López‐García(Hospital Universitario Fundación Jiménez Díaz), Deirdre O’Mahony(Bon Secours Hospital Cork), Nicole Wong Doo(The University of Sydney), Aline Clavert(Centre Hospitalier Universitaire d'Angers), Matthew Ku(St Vincent's Hospital Melbourne), Nada Hamad(UNSW Sydney), Laure Ricard(Sorbonne Université), Louise Roulin(Assistance Publique – Hôpitaux de Paris), Qin Liu(University of Science and Technology of China), Rubén Fernández(Hospital Universitario De Cabueñes), Chiara Rusconi(Fondazione IRCCS Istituto Nazionale dei Tumori), Johnathan Elliot(The Christie NHS Foundation Trust), Praveen Gounder(The University of Sydney), Marie‐Pierre Moles‐Moreau(Centre Hospitalier Universitaire d'Angers), Gavin Preston(University of Leeds), Teresa Calimeri(Harvard University)
UCL Discovery (University College London)
April 21, 2022
Cited by 76
Related Papers
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
|The Lancet Oncology|2022|429
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
|Journal of Clinical Oncology|2007|414